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ABSTRACT
The acute rejection of bone marrow (BM) allografts by host effectors can occur within a short period after
BM transplantation (BMT) in lethally irradiated mice. Common assays used to ascertain engraftment/
resistance involve measuring the growth of granulocyte/monocyte progenitors (colony-forming unit–
granulocyte-macrophage) in vitro or splenocyte proliferation assessed by radioisotope incorporation in
vivo 5 to 8 days after BMT. However, the correlation of the long-term outcome of BMT with the kinetics
of recovery by using the dose of allogeneic BM cells (BMCs) that leads to early rejection as determined by
the in vitro assessment has not been extensively studied. Thus, to investigate whether the early rejection
of donor BMCs is an indication of a long-term engraftment failure, C57BL/6 (H2b) mice were lethally
irradiated and transplanted with various doses of BALB/c (H2d) BMCs. The short-term engraftment of
donor precursors (colony-forming unit– granulocyte-macrophage), the kinetics of hematopoietic cell
recovery, the extent of donor chimerism, and the proportion of the recipients with long-term survival were
determined. The results show that the kinetics and extent of hematopoietic cell recovery were significantly
delayed in mice receiving limiting doses of BMCs that were rejected or severely resisted at day 8 after
BMT. However, a proportion of these mice survived up to 98 days after BMT with mixed chimerism or
donor chimerism. This study demonstrates that early rejection of BM precursors, as assessed by mea-
surement of myeloid progenitors in the spleen after BMT, does not always correlate with the long-term
outcome of the marrow allograft and that significant variability is inherent in the extent of chimerism when
threshold amounts of BMCs are used.
© 2005 American Society for Blood and Marrow Transplantation
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uNTRODUCTION
Bone marrow transplantation (BMT) or stem cell
ransplantation has been increasingly used in recent
ears as a treatment for neoplastic and nonneoplastic
iseases of hematologic or nonhematologic origin [1-5].
ecause of the scarcity of related HLA-matched donors,
one marrow (BM) allografts from related HLA-mis-
atched or HLA-matched unrelated donors are used in
llogeneic BMT. However, the efﬁcacy of allogeneic
MT is challenged by serious obstacles, most of which d
52re fatal. These obstacles include the failure of allograft
ngraftment, graft-versus-host disease (GVHD) medi-
ted by donor T cells contaminating the BM, relapse
rom the original tumor when used as a cancer therapy,
nd opportunistic infection due to severe immunosup-
ression resulting from the conditioning regimen for
MT [2,3,5,6]. Resolving one problem without worsen-
ng another poses a considerable challenge and contrib-
tes to the complexity of allogeneic BMT. For example,
epletion of T cells from the BM allograft to minimize
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Early versus Late BM Graft Rejection in Murine Allogeneic Transplantations
BVHD increases the incidence of engraftment failure of
onor cells because of the concurrent removal of en-
raftment-facilitating T cells [7-11].
Over the past couple of decades, the phenomenon
f BM cell (BMC) rejection/engraftment has been
ctively investigated. Previous studies have shown that
atural killer (NK) cells can reject BMC allografts in
ivo [12-15] and that the subsets of NK cells may play
ifferent roles in BMC rejection in mouse models of
MT [15-17]. However, the cell populations targeted
n BM allograft rejection are not clearly understood.
espite many years of research, an in vitro assay that
dequately reﬂects the immunogenetics of BM allo-
raft rejection in vivo is currently unavailable, and the
n vivo assays have remained unchanged. In these in
ivo assays, mice are given myeloablative condition-
ng, usually in the form of total body irradiation at
arious doses depending on the strain of mice, and
hen infused with BMCs intravenously [18]. At early
ime points within 2 weeks after BMT, the level of
MC engraftment is determined by measuring the
ematopoietic or granulocyte/monocyte progenitor
ell content (colony-forming unit–culture and colo-
y-forming unit–granulocyte-macrophage [CFU-
M]) in spleen or splenic incorporation of a radiola-
eled thymidine analog, 125I-iododeoxyuridine [14,18].
n previous studies using the in vivo assays, long-term
onor cell engraftment has not been assessed. Only in
tudies with experimental designs focused on long-term
onor chimerism has the percentage of donor cell chi-
erism been determined [19,20]. Furthermore, a di-
ect comparison of allogeneic BMT outcomes (early
ejection/engraftment, kinetics of hematopoietic
ell recovery, and long-term donor chimerism) us-
ng various doses of allogeneic BMCs, including one
hat results in early rejection, has not yet been
erformed. Therefore, we investigated whether
arly rejection of the BM allograft as indicated by a
urrently used assay is reﬂective of delayed or failed
ematopoietic cell recovery and long-term engraft-
ent of donor BMCs. In this report, we demon-
trate that (1) an early lack of growth of donor
MCs as measured by CFU-GM is reﬂected in
elayed hematopoietic cell recovery and (2) the lack
f growth of donor BMCs as measured by
FU-GM does not always reﬂect the level of long-
erm donor cell engraftment.
ATERIALS AND METHODS
ice
C57BL/6 (B6, H2b) and BALB/c (H2d) mice were
urchased from Jackson Laboratory (Bar Harbor,
E) and the Animal Production Area (National Can-
er Institute, Frederick, MD), respectively. All mice
ere kept in a speciﬁc pathogen–free condition and
sed at 8 to 14 weeks of age. H
B&MTone Marrow Transplantation
B6 mice were put on drinking water containing
.5% bleach (vol/vol) for 7 days before and after
MT, and at day 0, B6 mice were lethally irradiated
ith a single exposure of  irradiation from a 137Cs
ource (2.12 Gy/min) at 9.5 Gy. A single-cell suspen-
ion of BMCs from BALB/c mice was prepared in
ulbecco’s phosphate buffered saline and injected
nto the caudal vein of B6 recipients at 15  106, 5 
06, or 2.5  106 per mouse (intravenously) 2 hours
fter irradiation. For the purpose of discussion, the
MC dose at 15  106, 5  106, or 2.5  106 is
eferred to as high, intermediate, or low, respectively,
n the text. Mice were monitored for survival, and
nalyses determining the level of hematopoietic re-
onstitution were performed at various days after
MT, as described below.
hort-term Reconstitution Studies
At day 8 to 12 after BMT, mice transplanted with
.5  106, 5  106, or 15  106 BALB/c BMCs were
illed (3-5 mice per group per experiment), and a
ingle-cell suspension of each spleen was prepared.
wo hundred ﬁfty thousand or 5  105 splenocytes
ere cultured in colony assay medium (Iscove’s mod-
ﬁed Dulbecco’s medium containing 15% fetal bovine
erum, 100 U/mL penicillin/100 g/mL streptomy-
in, 2 mmol/L l-glutamine, 5  105 mol/L 2-mer-
aptoethanol, and 1.1% methylcellulose [wt/vol]) sup-
lemented with 10 ng/mL recombinant murine (rm)
ranulocyte-macrophage colony-stimulating factor
GM-CSF; AMGen Corporation, Thousand Oakes,
A) and 10 ng/mL rm interleukin-3 (Developmental
herapeutics Program, National Cancer Institute) in
35-mm petri dish in triplicate for 7 days in a humid-
ﬁed atmosphere at 37°C with 5% CO2. Granulocyte/
onocyte colonies were then enumerated on a stereo
icroscope (Nikon, Melville, NY).
omplete Blood Count Analysis
For assessing the kinetics of hematopoietic cell re-
overy, peripheral blood samples were collected weekly
rom 3 to 5 mice per group into ethylenediaminetet-
aacetic acid–treated Microtainer tubes (Becton Dickin-
on, San Jose, CA) for 6 weeks after BMT. The blood
amples were analyzed on a HEMAVET Multispecies
ematology Analyzer (CDC Technologies, Oxford,
T) to determine the complete blood count (CBC)
evels.
ntibodies
Fluorescein isothiocyanate (FITC)–conjugated anti-
ouse H2Dd (FITC-H2Dd); phycoerythrin (PE)–
onjugated anti-mouse H2Kb, CD4, and CD8 (PE-
2Kb, PE-CD4, and PE-CD8); biotinylated anti-mouse
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22Kb, immunoglobulin (Ig)M, CD4, CD8, and Gr-1
B-H2Kb, B-IgM, B-CD4, B-CD8, and B-Gr-1) anti-
odies; and Cy-Chrome–conjugated streptavidin (Cy-
A) were purchased from Pharmingen (San Diego, CA).
low Cytometric Analysis
At day 90 after BMT, BMCs, splenocytes, and thy-
ocytes were obtained from 2 to 7 mice per group for
-color staining. BMCs were labeled with B-Gr-1, and
plenocytes were stained with B-IgM or a combination
f B-CD4 and B-CD8 followed by Cy-SA. After wash-
ng, BMCs and splenocytes were labeled with FITC-
2Dd and PE-H2Kb. Thymocytes were labeled with
-H2Kb followed by Cy-SA and then stained further
ith FITC-H2Dd, PE-CD4, and PE-CD8. Labeled
amples were analyzed by using a FACScan and Cell
uest software (Becton Dickinson) to determine the
evel of donor chimerism.
tatistics
For assays examining the levels of CFU-GM,
BC, and donor cell chimerism, one-way analysis of
ariance with the Tukey multiple comparison test was
sed to determine statistically signiﬁcant differences
etween experimental groups. For statistical differ-
nces in the survival of animals in experimental
roups, the log-rank test was used.
ESULTS
he Growth of Granulocyte/Monocyte Progenitors
n Spleens from Mice Transplanted with
ntermediate and Low Doses of Allogeneic BMCs
as Severely Inhibited
To investigate the effects of different doses of
onor BMCs on the extent of engraftment versus
ejection of donor cells, an allogeneic BMT model
sing donor and recipient mice with full major histo-
ompatability complex mismatch was used. B6 (H2b)
ice were lethally irradiated at 9.5 Gy and trans-
lanted with 15  106 (high), 5  106 (intermediate),
r 2.5  106 (low) BALB/c (H2d) unfractionated
MCs. At day 8 to 12 after BMT, splenocytes were
arvested from the recipient mice and cultured in
olony assay media containing rm–interleukin 3 and
mGM-CSF for growth of granulocyte/monocyte
rogenitors to determine the level of early engraft-
ent after BMT. The number of CFU-GM in Figure
indicates the presence of signiﬁcantly more granu-
ocyte/monocyte progenitors in spleens from mice
econstituted with the high dose of BALB/c BMCs
ompared with either the intermediate or the low
ose. This suggests consistent engraftment of donor
ells at day 8 to 12 after BMT only with the high dose
f allogeneic BMCs.The effects of different doses of donor BMCs were a
54urther examined by monitoring the recipients for
urvival. None of the irradiation control group, which
id not receive allogeneic BMCs, survived beyond 2
eeks after BMT, thus indicating that a myeloablative
ose of total body irradiation was administered to the
ecipient animals (data not shown). The proportion of
urviving mice that received the intermediate dose
75% at day 98; average of 3 independent experi-
ents; Figure 1B) of BALB/c BMCs was not signiﬁ-
antly (P .071) lower than that of mice that received
he high dose of donor BMCs (93% at day 98). Al-
hough the proportion of surviving mice that received
he low dose was signiﬁcantly lower (P  .0012) com-
ared with the group that received the high dose, 57%
f animals survived up to day 98 after BMT (Figure
B). Hematocrits obtained from the moribund mice
ndicated that the animals succumbed to hematopoi-
tic aplasia (data not shown) between 9 and 45 days
igure 1. Overall survival and CFU-GM in spleens of recipients
fter allogeneic BMT. B6 recipients were lethally irradiated at 9.5
y and received various doses of BALB/c BMCs. A, At day 8 to 12
fter BMT, splenocytes were harvested from 3 mice per group in
ach experiment and plated in semisolid media containing rmGM-
SF and rm interleukin 3 as described in Materials and Methods.
he numbers represent mean  SEM. Statistical differences be-
ween groups were determined by analysis of variance with the
ukey multiple comparison test. B, B6 mice (30 to 31 mice per
roup) that had undergone transplantation were monitored for
urvival. Pooled data from 3 independent experiments are shown,
nd statistical differences were determined by the log-rank test.fter BMT. Clinical evidence of GVHD was not ob-
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Berved, and this is consistent with our previous expe-
ience, in which additional donor T cells were
equired for GVHD in this strain combination, even
ith the highest dose of BMCs used in this study
21,22]. These results demonstrate that measuring the
resence and growth of donor granulocyte/monocyte
rogenitors (CFU-GM) in the spleen shortly after
MT may be an overestimation of the extent of donor
ell rejection, as determined by successful hematopoi-
tic rescue in a proportion of mice.
ntermediate and Lower Amounts of Allogeneic
MCs Result in Delayed Recovery of Mature
ematopoietic Cells after BMT
Although a large proportion of the animals recon-
tituted with 5  106 or 2.5  106 BALB/c BMCs
xhibited long-term survival, hematopoietic cell re-
overy may be delayed in these mice compared with
hat in mice reconstituted with the high dose of BMCs
ecause of the lower number of hematopoietic pro-
enitors expected in the lower doses of BMCs. There-
ore, peripheral blood samples were collected every
eek from 3 to 5 mice per group for 6 weeks to assess
he levels of hematopoietic cell recovery. The results
ndicate that all cellular parameters of peripheral
lood were indeed affected by the dose of allogeneic
MCs used in the BMT. The levels of total white
lood cells (WBCs), neutrophils, and lymphocytes
ere signiﬁcantly suppressed in mice that received the
ntermediate and low doses of BALB/c BMCs for the
igure 2. Delayed kinetics of hematopoietic cell recovery in periph
ere lethally irradiated at 9.5 Gy and injected with BALB/c BMCs
lood samples were collected weekly (3-5 mice per group per experim
ed blood cells, and platelets recovered after BMT as described in
hown. Stars represent statistical differences compared with the gro
ariance with the Tukey multiple comparison test.rst 2 weeks (Figure 2). However, the WBC, neutro- t
B&MThil, and lymphocyte levels were normalized by 4
eeks after BMT and were maintained at the normal
evel during the remaining period until the animals
ere killed at day 90 (data not shown). The level of
ed blood cells was most signiﬁcantly affected in mice
hat received the intermediate or low dose of BMCs,
nd this inhibition was sustained up to 5 weeks after
MT. Similarly, platelet recovery was signiﬁcantly
elayed for 4 weeks in mice that received the inter-
ediate or low dose compared with that in mice that
eceived the high dose of BMCs and was not normal-
zed until 5 weeks after BMT. These results demon-
trate that the kinetics of recovery of mature periph-
ral blood elements are also affected and are
ontingent on the donor marrow dose.
t Day 90 after BMT, Mice That Received the
ow Dose of Allogeneic BMCs Had Fewer
onor-Derived Cells Than Mice That Received the
ntermediate or High Dose of Allogeneic BMCs
To assess the effect of allogeneic BMC doses on
he extent of long-term donor chimerism, the total
nd donor-derived cell numbers in the BM, spleen,
nd thymus of individual recipients were determined
y ﬂow cytometric analysis at day 90 after BMT. At
ay 90 after BMT, a considerable decrease in total cell
umbers recovered in spleen and thymus in animals
econstituted with the low dose of BMCs was ob-
erved compared with mice that received the high
ose of BMCs (Figure 3B and C). More importantly,
od in mice that received limited doses of BMC allografts. B6 mice
nously) at 1.5  107, 5  106, or 2.5  106 per mouse. Peripheral
nd analyzed for the levels of total WBCs, neutrophils, lymphocytes,
ls and Methods. Pooled data from 3 independent experiments are
t received 1.5  107 BALB/c BMCs, as determined by analysis oferal blo
(intrave
ent) a
Materia
up thahe level of donor-derived cells in the BM, spleen, and
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2hymus in these mice was signiﬁcantly lower (Figure
), and 66% of the animals completely rejected the
onor cells (Figure 4). Nevertheless, donor cell chi-
erism could still be observed in a few mice recon-
tituted with the low dose of BMCs. It is interesting to
ote that there was signiﬁcant variability regarding
he extent of chimerism: this group showed a range of
onor cell engraftment. Unlike the level of donor
himerism observed in the group that received the low
ose of BMCs, the number of total and donor-derived
igure 3. The effect of dose of BMC allograft on long-term donor
rradiated at 9.5 Gy and injected with BALB/c BMCs (intravenously
MCs, splenocytes, and thymocytes were isolated from the recipien
ollowed by Cy-SA and then with FITC-H2Dd and PE-H2Kb. Th
ITC-H2Dd and a mixture of PE-CD4 and PE-CD8. Splenocytes w
ith a FACScan cell analyzer using Cell Quest software. A pool of 2
roups were determined by analysis of variance with the Tukey muells recovered in mice reconstituted with the inter- B
56ediate dose of BALB/c BMCs was not signiﬁcantly
ifferent from that in mice that received the high dose
Figure 3). This result was also contrary to the early
ejection of the intermediate dose indicated by colony
ssays at day 8 to 12. The assessment of the level of
onor chimerism in splenic T- and B-cell populations
ndicates that the percentage of donor-derived T and
cells was signiﬁcantly lower at day 90 after BMT in
ice that were infused with the low dose than in
nimals that received the intermediate or high dose of
graftment in the bone marrow and thymus. B6 mice were lethally
 107, 5  106, or 2.5  106 per mouse, and at day 90 after BMT,
mice per group per experiment). BMCs were stained with B-Gr-1
tes were stained with B-H2Kb followed by Cy-SA and then with
ined with FITC-H2Dd and PE-H2Kb. Stained cells were analyzed
ndent experiments is shown, and the statistical differences between
omparison test.cell en
) at 1.5
ts (2-7
ymocy
ere sta
indepeMCs (Figure 4). These results demonstrate that (1)
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Early versus Late BM Graft Rejection in Murine Allogeneic Transplantations
BB&MThe early rejection of donor BMCs measured by the
evel of myeloid reconstitution at day 8 to 12 after
MT does not always correlate with the level of long-
erm donor cell engraftment; (2) the intermediate or
ow dose is more severely resisted compared with the
igh dose of allogeneic BMCs by lethally irradiated
ecipients, as measured in the short-term reconstitu-
ion assay; and (3) a high degree of donor chimerism
an be achieved in mice reconstituted with the inter-
ediate dose of allogeneic BMCs despite the early
eduction of myeloid progenitors.
ISCUSSION
In this study, we investigated the short- and long-
erm engraftment of fully mismatched BM allografts
n lethally irradiated mice by using various doses of
onor BMCs. The results from CFU-GM assay show
hat the extent of early graft rejection is dose depen-
ent: 5  106 and 2.5  106 BALB/c BMCs are
everely resisted or completely rejected by lethally
rradiated B6 recipients. However, 57% to 75% of
ice reconstituted with the limiting (low and inter-
ediate) doses of allogeneic BMCs survived long
erm, and mixed or nearly 100% donor cell chimerism
as achieved in many of the recipients. This shows
hat the early rejection of donor cells indicated by
olony-forming assays does not necessarily imply the
ailure of long-term engraftment.
It has been previously reported that pluripotential
rogenitors contribute to engraftment for only a lim-
ted period of time, and it is hematopoietic stem cells
hat primarily contribute to long-term engraftment
23,24]. Therefore, colony-forming assays performed
hortly (5-13 days, depending on the experimental
ystem) after BMT most likely assess the engraftment
f a stem cell subpopulation or progenitors with fur-
her differentiation, which predominantly contribute
o short-term reconstitution and may not have a direct
ffect on the long-term engraftment of donor cells.
Although inhibition of CFU-GM growth did not
lways indicate the failure of long-term donor cell
ngraftment, it did correlate with the kinetics of he-
atopoietic cell recovery after BMT. The CBC anal-
sis of peripheral blood demonstrates that the rate of
econstitution in recipients that received the interme-
iate or low dose of allogeneic BMCs was delayed
igniﬁcantly compared with those reconstituted with
he high dose, especially during the ﬁrst 3 to 4 weeks
fter BMT. The hematopoietic cells recovered in re-
ipient animals early after BMT may arise from pro-
enitors, which contribute to short-term reconstitu-
ion. Using puriﬁed CD34 stem cells, Uchida et al.
25] and Weissman [26] have shown that the higher
he dose of stem cells, the shorter the time required
or hematopoietic recovery in peripheral blood afterigure 4. The effect of dose of BMC allograft on the percentage of
onor cell chimerism. B6 mice were lethally irradiated at 9.5 Gy and
njected with BALB/c BMCs (intravenously) at 1.5  107, 5  106,
r 2.5  106 per mouse, and at day 90 after BMT, splenocytes were
solated from the recipients (2-7 mice per group per experiment).
onor- versus host-derived cells were determined by ﬂow cytomet-
ic analysis as described in Materials and Methods. A pool of 2
ndependent experiments is shown, and the statistical differences
etween groups were determined by analysis of variance with theyngeneic or allogeneic stem cell transplantation. Ad-
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2itionally, 23% to 43% of mice that received the
ower doses of BMCs succumbed to hematopoietic
ailure, and this suggests that there may be a threshold
f short-term repopulating cells that is required to
ustain the survival of mice until the subset of stem
ells responsible for long-term reconstitution takes
ver. Thus, delayed recovery of hematopoietic cells in
ice transplanted with the lower doses of BMCs may
eﬂect fewer early repopulating progenitors remaining
fter allograft resistance.
Despite the severe resistance of engraftment of
hort-term repopulating donor cells and the decrease
n the kinetics of hematopoietic cell recovery during
he ﬁrst 3 to 4 weeks after BMT, long-term donor cell
himerism determined at day 90 demonstrated that
he intermediate dose of BALB/c BMCs (5  106) can
chieve multilineage engraftment as high as can the
igh dose (15  106) in B6 recipients, except for the
-cell compartment. In addition to NK cells mediat-
ng acute rejection of BM allografts in lethally irradi-
ted mice [27,28], a recent report has shown that both
-cell receptor 	 and T-cell receptor 
 T cells
re the major players of host resistance to allogeneic
MC engraftment in recipients conditioned with sub-
ethal irradiation [20]. However, the effect of engraft-
ent-facilitating T cells in the BM allograft is well
stablished, and Jiang et al. [29] have demonstrated
he importance of the cytotoxic effector function of
D8 donor T cells in long-term donor cell chimer-
sm. Therefore, mixed chimerism observed in the T-
ell compartment may reﬂect the consequence of the
nteraction between donor and host T cells. In lethally
rradiated mice, few irradiation-resistant T cells can
ediate resistance to donor cells. When a high dose of
nfractionated allogeneic BMCs is transferred into
ethally irradiated recipients, as in this report, donor T
ells present in the BM inoculum may be sufﬁcient to
verride host T cell–mediated resistance. However, if
ewer T cells are present in the donor BM graft as a
esult of the lower doses used in transplantation, the
alance of the donor/host T-cell interaction may tilt
oward the host resistance and lead to decreased en-
raftment of the donor T-cell lineage. In addition,
esidual host hematopoietic precursors, although in-
ufﬁcient to provide radioprotection in the absence of
onor marrow support, can provide long-term recon-
titution under appropriate transplantation condi-
ions. Most importantly, in this study we demonstrate
hat the 2 classic measurements of rejection in exper-
mental models (short-term assays versus demonstra-
ion of long-term chimerism) do not always correlate.
lthough the presence of graft-facilitating cells (ie, T
ells) in the unfractionated BM grafts used in this
tudy, the extent of donor and recipient mismatch at
oth the major histocompatability complex and the
iller cell immunoglobulin-like receptor (KIR) loci,
nd the number of hematopoietic stem cells can in- p
58uence the kinetics of reconstitution, the lack of
greement between short- and long-term measures in
his study underscores the importance of not relying
n only one or the other assay to investigate the
echanisms of rejection.
Most surviving mice, which received the low dose
f BALB/c BMCs, rejected the donor cells and were
epopulated by host-derived cells, correlated with the
nhibition observed in CFU-GM assay at day 8 to 12
fter BMT and the delay of hematopoietic cell recov-
ry in peripheral blood. Nevertheless, a few of these
ecipients exhibited a comparable percentage of donor
ell chimerism even though the number of donor cells
as markedly lower than in the animals that received
he high or intermediate dose of BALB/c BMCs. This
bservation is consistent with predicted outcomes
hen threshold levels of graft cells are used. These
bservations underscore the fact that the degree to
hich a correlation can be made between the assays
urrently used to assess short- and long-term engraft-
ent depends on the dose of BMCs used in the trans-
lantation. The doses of allogeneic BMCs used in
tudies investigating the mechanisms of BM allograft
ejection with mouse models vary depending on the
train combinations of donor and recipient mice and
ay not represent the lowest possible dose that leads
o both early rejection and long-term engraftment
ailure. However, in most of these studies, conclusions
egarding the engraftment or rejection of limiting
oses of BM allografts are drawn on the basis of the
arly rejection determined by colony assays or in vivo
roliferation assays alone. Data presented in this re-
ort demonstrate that there are disparate outcomes
etween currently available assays determining short-
nd long-term engraftment of donor cells. Therefore,
esults from short-term engraftment assays should be
nterpreted only with regard to the early repopulating
rogenitors. Furthermore, this study demonstrates the
ecessity of a novel method or methods that can assess
oth short- and long-term engraftment of donor cells
or complete delineation of mechanisms of BM allo-
raft rejection: this is essential for steps toward over-
oming engraftment failure and, thus, improving the
fﬁcacy of allogeneic BMT.
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